Key result
Levodopa markedly improves gait and reduces chorea in half of treated benign hereditary chorea patients.
Why the study?
A novel nonsense mutation in the TITF-1 gene causing benign hereditary chorea with congenital hypothyroidism was identified, and the therapeutic response to levodopa was unclear.
Does levodopa improve symptoms in patients with benign hereditary chorea caused by a TITF-1 mutation?
Case Report (n=4)
Does levodopa improve symptoms in patients with benign hereditary chorea caused by a TITF-1 mutation?
Levodopa may be a useful therapeutic option for improving gait and reducing chorea in patients with benign hereditary chorea.
Answers are grounded in this paper and cite their sources.
May merit levodopa trial in select TITF-1 cases; hypothesis-generating and requires controlled validation before practice change.
Presented is a pedigree with infancy-onset benign hereditary chorea (BHC) caused by a novel nonsense mutation in exon 3 (523G-->T, E175X) of the TITF-1 (Nkx2.1) gene. Four confirmed mutation carriers showed the typical movement disorder of BHC and congenital hypothyroidism. Surprisingly, treatment with levodopa improved gait dramatically and reduced chorea in two patients. Dopaminergic drugs should be considered a useful therapeutic option in BHC.
No takes yet. Share an insight, caveat, or question.
Asmus et al. (2005) conducted a case report in Benign hereditary chorea (BHC) and congenital hypothyroidism (n=4). Levodopa was evaluated on Improvement in gait and reduction in chorea. Treatment with levodopa dramatically improved gait and reduced chorea in two out of four patients with benign hereditary chorea caused by a novel TITF-1 mutation.
Synapse has enriched 10 related papers. Consider them for comparative context: